-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Chemed, Raises Price Target to $667

Benzinga·03/14/2025 15:37:50
Listen to the news
RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $633 to $667.